Targeting multiple domains of residual cardiovascular disease risk in patients with diabetes.

ABSTRACT:

Purpose of review

There has been a recent resurgence of diabetes-related cardiovascular complications after years of steady improvement. This review highlights established and emerging contemporary secondary prevention approaches that lower the risk of atherosclerotic and nonatherosclerotic cardiovascular disease events among patients with diabetes.

Recent findings

Secondary prevention therapies modify residual risk targets, including cardiometabolic pathways, lipoproteins, thrombosis, and inflammation. Large-scale clinical trials of sodium-glucose cotransporter-2 inhibitors have demonstrated significant reductions in hospitalization for heart failure. Glucagon-like peptide-1 receptor agonists have reduced the risk of major adverse cardiovascular events. Recent clinical tria

SUBMITTER: Patel KV 

PROVIDER: S-EPMC8855785 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature